Monday, March 30, 2020
AbbVie will stop enforcing global patent rights on...
...its HIV drug, Kaletra, amid the
COVID-19 pandemic. The drug has entered several clinical trials to test its
performance in treating the coronavirus, and the move will greatly improve
worldwide access to the drug in the event of shortages. In the U.S., Kaletra
currently holds preferred formulary status for 61% of all covered lives.
SOURCE: MMIT Analytics, as
of 3/25/20
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment